Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 3, 2026.
Summary
- Option exercise/conversion: acquired 8,910 Common Stock at $135.42 ($1,206,592) on September 3, 2026; holds 333,353 after (Indirect).
- Option exercise/conversion: acquired 590 Common Stock at $117.76 ($69,478) on September 3, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $479.07 ($95,813) on September 3, 2026; holds 333,743 after (Indirect).
- Open-market sale: disposed of 440 Common Stock at $480.53 ($211,431) on September 3, 2026; holds 333,303 after (Indirect).
- Open-market sale: disposed of 600 Common Stock at $481.47 ($288,884) on September 3, 2026; holds 332,703 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $482.35 ($192,938) on September 3, 2026; holds 332,303 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $483.69 ($38,695) on September 3, 2026; holds 332,223 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $485.16 ($116,438) on September 3, 2026; holds 331,983 after (Indirect).
- Open-market sale: disposed of 411 Common Stock at $486.72 ($200,044) on September 3, 2026; holds 331,572 after (Indirect).
- Open-market sale: disposed of 1,429 Common Stock at $487.87 ($697,160) on September 3, 2026; holds 330,143 after (Indirect).
- Open-market sale: disposed of 1,604 Common Stock at $488.68 ($783,847) on September 3, 2026; holds 328,539 after (Indirect).
- Open-market sale: disposed of 3,114 Common Stock at $489.62 ($1,524,667) on September 3, 2026; holds 325,425 after (Indirect).
- Open-market sale: disposed of 940 Common Stock at $490.50 ($461,070) on September 3, 2026; holds 324,485 after (Indirect).
- Open-market sale: disposed of 42 Common Stock at $491.25 ($20,632) on September 3, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 8,910 Stock Option on September 3, 2026 (Indirect).
- Option exercise/conversion: disposed of 590 Stock Option on September 3, 2026; holds 499,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,631,619 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Option exercise/conversion | Common Stock | 8,910 | $135 | $1.2M | 333,353 |
| 2026-09-03 | Option exercise/conversion | Common Stock | 590 | $118 | $69.5K | 333,943 |
| 2026-09-03 | Open-market sale | Common Stock | 200 | $479 | $95.8K | 333,743 |
| 2026-09-03 | Open-market sale | Common Stock | 440 | $481 | $211.4K | 333,303 |
| 2026-09-03 | Open-market sale | Common Stock | 600 | $481 | $288.9K | 332,703 |
| 2026-09-03 | Open-market sale | Common Stock | 400 | $482 | $192.9K | 332,303 |
| 2026-09-03 | Open-market sale | Common Stock | 80 | $484 | $38.7K | 332,223 |
| 2026-09-03 | Open-market sale | Common Stock | 240 | $485 | $116.4K | 331,983 |
| 2026-09-03 | Open-market sale | Common Stock | 411 | $487 | $200.0K | 331,572 |
| 2026-09-03 | Open-market sale | Common Stock | 1,429 | $488 | $697.2K | 330,143 |
| 2026-09-03 | Open-market sale | Common Stock | 1,604 | $489 | $783.8K | 328,539 |
| 2026-09-03 | Open-market sale | Common Stock | 3,114 | $490 | $1.5M | 325,425 |
| 2026-09-03 | Open-market sale | Common Stock | 940 | $491 | $461.1K | 324,485 |
| 2026-09-03 | Open-market sale | Common Stock | 42 | $491 | $20.6K | 324,443 |
| 2026-09-03 | Option exercise/conversion | Stock Option | 8,910 | — | — | 0 |
| 2026-09-03 | Option exercise/conversion | Stock Option | 590 | — | — | 499,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Option exercise/conversion (8,910 shares) |
| 2026-09-03 | Option exercise/conversion (590 shares) |
| 2026-09-03 | Open-market sale (200 shares) |
| 2026-09-03 | Open-market sale (440 shares) |
| 2026-09-03 | Open-market sale (600 shares) |
| 2026-09-03 | Open-market sale (400 shares) |
| 2026-09-03 | Open-market sale (80 shares) |
| 2026-09-03 | Open-market sale (240 shares) |
| 2026-09-03 | Open-market sale (411 shares) |
| 2026-09-03 | Open-market sale (1,429 shares) |
| 2026-09-03 | Open-market sale (1,604 shares) |
| 2026-09-03 | Open-market sale (3,114 shares) |
| 2026-09-03 | Open-market sale (940 shares) |
| 2026-09-03 | Open-market sale (42 shares) |
| 2026-09-03 | Option exercise/conversion (8,910 shares) |
| 2026-09-03 | Option exercise/conversion (590 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.